BioMarin (BMRN) Stock: The Patent Fight Is Over and BioMarin Won Royalties
Ascendis will pay royalties to BioMarin and the companies will dismiss patent claims in the United States, Europe, Brazil and South Korea.
7 Articles
7 Articles
BioMarin Pharmaceutical and Ascendis Pharma announced an agreement to close global legal disputes, including actions in Brazil, Germany, Denmark, South Korea and the United States. The litigation involved Yuviwel, developed by Ascendis, and patents related to the C-type natriuretic peptide technology (CNP), applied to the treatment of rare genetic conditions, such as BioMarin's achondroplasia. By the agreement, Ascendis will pay BioMarin royalti…
PR Newswire
The AI JournalBioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the...
BioMarin (BMRN) Stock Secures Victory in Patent Dispute, Gains Royalty Stream Through 2030
BioMarin (BMRN) stock adds royalty revenue after patent settlement with Ascendis Pharma over CNP technology, securing payments through May 2030. The post BioMarin (BMRN) Stock Secures Victory in Patent Dispute, Gains Royalty Stream Through 2030 appeared first on Blockonomi.
BioMarin (BMRN) Stock: The Patent Fight Is Over and BioMarin Won Royalties
TLDR BioMarin and Ascendis Pharma reached a global settlement resolving all patent disputes over Ascendis’s drug Yuviwel. Ascendis will pay BioMarin a 20% royalty on U.S. net sales and 18% on sales in the EU, Brazil, and South Korea. Royalty payments are retroactive to Yuviwel’s first commercial...
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - PressReach
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis’s Yuviwel. … Continue reading "BioMarin An…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
